Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10908818 | Leukemia Research | 2014 | 8 Pages |
Abstract
We performed a retrospective population-based study using the SEER database to assess survival trends in CBF-AML between 2000 and 2010. Median OS increased from 16 months in 2000-2002 to 25 months in 2006-2008 (PÂ =Â 0.002). The 3-year OS rate for patients with inv(16) was 57.3%, but in t(8;21) was only 35.5%. Patients aged 75-84 had worse survival than patients aged 15-44 (HR 5.61, PÂ =Â 0.0002). Black race was associated with higher mortality (HR 1.50, PÂ =Â 0.03). Compared to clinical trial outcomes, CBF-AML survival is poorer in the general population, particularly among African Americans and the elderly, and in t(8;21) compared to inv(16) AML.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Andrew M. Brunner, Traci M. Blonquist, Hossein Sadrzadeh, Ashley M. Perry, Eyal C. Attar, Philip C. Amrein, Karen K. Ballen, Yi-Bin Chen, Donna S. Neuberg, Amir T. Fathi,